Trials / Completed
CompletedNCT00146003
Efalizumab for Eczema
Investigator-Initiated Trial of Efalizumab for Atopic Dermatitis: A Proof of Concept Study in Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (planned)
- Sponsor
- University of Medicine and Dentistry of New Jersey · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate a measurable improvement on a validated scale in a small population of adult patients with atopic dermatitis (eczema).
Detailed description
The study involves administration of efalizumab (previously approved for psoriasis) to ten adult patients with atopic dermatitis. Biologic plausibility rests on similarities in pathophysiology of the two conditions. The drug (efalizumab) will be administered according to the dosing approved for plaque psoriasis for a period of 24 weeks. The subjects will self-administer efalizumab weekly and measurements will be performed on a monthly basis. Efalizumab is not being compared to placebo or other drugs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Efalizumab treatment |
Timeline
- Start date
- 2005-03-01
- Completion
- 2007-12-01
- First posted
- 2005-09-05
- Last updated
- 2008-08-07
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00146003. Inclusion in this directory is not an endorsement.